Your browser doesn't support javascript.
loading
NLRP3 Inflammasome Activation Is Involved in LPA1-Mediated Brain Injury after Transient Focal Cerebral Ischemia.
Lee, Chi-Ho; Sapkota, Arjun; Gaire, Bhakta Prasad; Choi, Ji Woong.
Afiliação
  • Lee CH; Laboratory of Neuropharmacology, College of Pharmacy and Gachon Institute of Pharmaceutical Sciences, Gachon University, Incheon 21936, Korea.
  • Sapkota A; Laboratory of Neuropharmacology, College of Pharmacy and Gachon Institute of Pharmaceutical Sciences, Gachon University, Incheon 21936, Korea.
  • Gaire BP; Laboratory of Neuropharmacology, College of Pharmacy and Gachon Institute of Pharmaceutical Sciences, Gachon University, Incheon 21936, Korea.
  • Choi JW; Laboratory of Neuropharmacology, College of Pharmacy and Gachon Institute of Pharmaceutical Sciences, Gachon University, Incheon 21936, Korea.
Int J Mol Sci ; 21(22)2020 Nov 14.
Article em En | MEDLINE | ID: mdl-33202644
ABSTRACT
Lysophosphatidic acid receptor 1 (LPA1) contributes to brain injury following transient focal cerebral ischemia. However, the mechanism remains unclear. Here, we investigated whether nucleotide-binding oligomerization domain-like receptor family pyrin domain containing 3 (NLRP3) inflammasome activation might be an underlying mechanism involved in the pathogenesis of brain injury associated with LPA1 following ischemic challenge with transient middle cerebral artery occlusion (tMCAO). Suppressing LPA1 activity by its antagonist attenuated NLRP3 upregulation in the penumbra and ischemic core regions, particularly in ionized calcium-binding adapter molecule 1 (Iba1)-expressing cells like macrophages of mouse after tMCAO challenge. It also suppressed NLRP3 inflammasome activation, such as caspase-1 activation, interleukin 1ß (IL-1ß) maturation, and apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) speck formation, in a post-ischemic brain. The role of LPA1 in NLRP3 inflammasome activation was confirmed in vitro using lipopolysaccharide-primed bone marrow-derived macrophages, followed by LPA exposure. Suppressing LPA1 activity by either pharmacological antagonism or genetic knockdown attenuated NLRP3 upregulation, caspase-1 activation, IL-1ß maturation, and IL-1ß secretion in these cells. Furthermore, nuclear factor-κB (NF-κB), extracellular signal-regulated kinase 1/2 (ERK1/2), and p38 were found to be LPA1-dependent effector pathways in these cells. Collectively, results of the current study first demonstrate that LPA1 could contribute to ischemic brain injury by activating NLRP3 inflammasome with underlying effector mechanisms.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Lesões Encefálicas / Lisofosfolipídeos / Ataque Isquêmico Transitório / Sistema de Sinalização das MAP Quinases / Receptores de Ácidos Lisofosfatídicos / Proteína 3 que Contém Domínio de Pirina da Família NLR Tipo de estudo: Etiology_studies Limite: Animals Idioma: En Revista: Int J Mol Sci Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Lesões Encefálicas / Lisofosfolipídeos / Ataque Isquêmico Transitório / Sistema de Sinalização das MAP Quinases / Receptores de Ácidos Lisofosfatídicos / Proteína 3 que Contém Domínio de Pirina da Família NLR Tipo de estudo: Etiology_studies Limite: Animals Idioma: En Revista: Int J Mol Sci Ano de publicação: 2020 Tipo de documento: Article